View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsViewRay 과거 순이익 실적과거 기준 점검 0/6ViewRay 의 수입은 연평균 -6.6%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 13.6%의 비율로 증가했습니다. 매출은 연평균 3%의 비율로 증가해 왔습니다.핵심 정보-6.60%순이익 성장률13.66%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률2.95%자기자본이익률-199.82%순이익률-104.30%최근 순이익 업데이트31 Mar 2023최근 과거 실적 업데이트Reported Earnings • May 12First quarter 2023 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.14 loss in 1Q 2022). Revenue: US$22.5m (up 19% from 1Q 2022). Net loss: US$28.9m (loss widened 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.공시 • May 10ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023ViewRay, Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023Reported Earnings • Mar 01Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.59 loss per share (improved from US$0.67 loss in FY 2021). Revenue: US$102.2m (up 46% from FY 2021). Net loss: US$107.3m (loss narrowed 2.5% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.공시 • Feb 01ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023ViewRay, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023Reported Earnings • Aug 03Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.15 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$22.1m (up 47% from 2Q 2021). Net loss: US$27.6m (loss narrowed 11% from 2Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.14 loss per share (up from US$0.17 loss in 1Q 2021). Revenue: US$18.9m (up 22% from 1Q 2021). Net loss: US$25.8m (loss narrowed 3.6% from 1Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 43%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • Oct 27Motion For Case Conversion Approved for ViewRay, Inc.The US Bankruptcy Court gave an order granting the conversion of Chapter 11 reorganization of ViewRay, Inc. to liquidation under Chapter 7 on October 26, 2023. The debtor was facing losses in the business.공시 • Sep 08Nasdaq To Delist the Common Stock of ViewRayNasdaq announced that it will delist the common stock of ViewRay, Inc. ViewRay, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time.공시 • Jul 27ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite IndexViewRay, Inc. has been dropped from Nasdaq Composite Index.공시 • Jul 24ViewRay Announces Commencement of Nasdaq Delisting ProceedingsViewRay, Inc. announced that on July 17, 2023 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’). Nasdaq has determined that due to the Company’s voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company’s ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company’s securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq’s determination. Trading of the company’s common stock will be suspended at the opening of business on July 26, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (‘SEC’), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Once the delisting from Nasdaq takes effect, the Company’s common stock is expected to begin trading on the over-the counter (‘OTC’) markets. On the OTC market, shares of the Company’s common stock, which previously traded on Nasdaq under the symbol ‘VRAY’, are expected to trade under the symbol ‘VRAYQ’. The transition to the OTC markets will not affect the Company’s intention to continue to operate in the normal course while in chapter 11. The Company will remain subject to the public reporting requirements of the SEC following the transfer.공시 • Jul 23ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the BoardViewRay, Inc. announced that on July 19, 2023, Mr. Sai Nanduri, a Senior Investment Analyst employed by Hudson Executive Capital LP, informed the Board of Directors of the Company that Mr. Nanduri was resigning from his position as an observer to the Board, effective immediately.공시 • Jul 17+ 1 more updateMotion for Joint Administration Filed by ViewRay, Inc.ViewRay, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on July 16, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, ViewRay Technologies, Inc., with its own case for administrative and procedural purposes. ViewRay, Inc. has been proposed as the lead debtor.공시 • Jul 10Viewray, Inc. Announces Resignation of Susan Schnabel from Board of DirectorsOn July 1, 2023, Susan Schnabel advised the Board of Directors (the “Board”) of ViewRay, Inc. (the “Company”) of her resignation from the Board, effective immediately. Ms. Schnabel’s resignation from the Board did not result from a disagreement with the Company or any of its officers or other directors on any matters relating to the operations, policies or practices of the Company.공시 • Jul 03ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketOn June 26, 2023, ViewRay, Inc. received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company does not currently meet the minimum closing bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Global Market at this time. The Notification Letter states that the Company has an automatic period of 180 calendar days to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the 180 calendar day period. If the Company does not achieve compliance with the minimum closing bid price requirement during the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day period if it applies to transfer the listing of the common stock to the Nasdaq Capital Market. To qualify, the Company must meet the continued listing requirement for the applicable market value of publicly held shares requirement and all other applicable initial listing standards for the Nasdaq Capital Market (except for the minimum bid price requirement) based on the Company’s most recent public filings and market information and provide written notice of its intention to cure the minimum bid price deficiency. If Nasdaq determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance with the listing requirements. The Company is committed to regaining compliance with the minimum closing bid price requirement prior to the expiration of all applicable compliance periods.Reported Earnings • May 12First quarter 2023 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.14 loss in 1Q 2022). Revenue: US$22.5m (up 19% from 1Q 2022). Net loss: US$28.9m (loss widened 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 12Consensus revenue estimates decrease by 16%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$108.0m to US$90.8m. EPS estimate unchanged from -US$0.58 per share at last update. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$1.95 unchanged from last update. Share price fell 20% to US$0.83 over the past week.공시 • May 10ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023ViewRay, Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023분석 기사 • Apr 17Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% LowerThe ViewRay, Inc. ( NASDAQ:VRAY ) share price has fared very poorly over the last month, falling by a substantial 63...Major Estimate Revision • Apr 14Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$135.8m to US$119.8m. EPS estimate increased from -US$0.602 to -US$0.585 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$7.00 to US$5.83. Share price fell 59% to US$1.30 over the past week.Reported Earnings • Mar 01Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.59 loss per share (improved from US$0.67 loss in FY 2021). Revenue: US$102.2m (up 46% from FY 2021). Net loss: US$107.3m (loss narrowed 2.5% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.공시 • Feb 01ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023ViewRay, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023공시 • Jan 22ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of DirectorsViewRay, Inc. announced that it has reached an agreement with Hudson Executive Capital LP to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors, effective as of January 20, 2023. The Company has also agreed that the Board will appoint Mr. Nanduri to fill any vacancy on the Board arising during the term of the agreement.공시 • Jan 13ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage TrialViewRay, Inc. announced that findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy -- delivered with MRIdian -- to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also associated with significantly better patient- reported quality of life metrics. The MIRAGE trial was led by Amar Kishan, M.D. (first author) and Michael L. Steinberg, M.D. (senior author) at the University of California, Los Angeles (UCLA). The study was independently designed, conducted, and analyzed exclusively by UCLA. In this trial, the investigator team randomized 156 patients to receive either MRI-guided SBRT or CT-guided SBRT. Acute grade >=2 GU toxicity rates were significantly lower with MRI guidance vs. CT guidance (24.4% in the MRI group vs. 43.4% in the CT group). Acute grade >=2 GI toxicity rates were also significantly lower with MRI guidance (0.0% in the MRI group vs. 10.5% in the CT group). On multivariate analysis, which controls for differences in the use of a rectal spacer, prostate size, and baseline urinary symptoms, the MRI-guided arm was associated with a 60% reduction in odds of grade >=2 GU toxicity. More notably, there were improvements in multiple patient-reported outcomes. Significantly more patients receiving CT- guided SBRT experienced large increases in urinary symptoms, as measured by a >15 points increase in International Prostate Symptom Score (IPSS) (6.8% in the MRI group vs. 19.4% in the CT group). Similarly, a significantly greater percentage of patients experienced a clinically notable decrease in bowel-related quality of life with CT-guided, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC-26) survey (25.0% in the MRI group vs. 50.0% in the CT group). Finally, though it is too early to conclude, as more than 2/3rds of men on the trial received hormonal therapy, exploratory analysis in men who did not receive hormonal therapy showed that patient-reported sexual-function scores (by EPIC-26) decreased more in men receiving CT-guided SBRT. To date, more than 27,000 patients have been treated with MRIdian. Currently, 56 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.공시 • Jan 10ViewRay, Inc. Announces CFO ChangesEffective January 9, 2023, William P. “Bill” Burke has been appointed as Chief Financial Officer of ViewRay, Inc. He will succeed Zach Stassen in that capacity, who has stepped down after serving the company since April 2020. Mr. Burke will become a member of the company’s executive leadership team, reporting directly to Scott Drake, President and Chief Executive Officer and will lead all aspects of the company’s finance function including business planning and analysis, accounting, SEC reporting, internal audit, tax, treasury, and investor relations. Mr. Burke, 54, is a seasoned executive, who brings over 25 years of global financial and operational experience to ViewRay. He previously served as the Chief Financial Officer at Haemonetics, a global blood management solutions company, from August 2016 to April 2022 and stayed on in an advisory capacity through June 2022. From July 2014 to July 2016, Mr. Burke served as Chief Integration Officer and Vice President, Integration for Medtronic, plc, a global healthcare products company and was a member of its Executive Committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, Mr. Burke spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Previously, he also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. Since January 2022 Mr. Burke has served on the board of directors and as audit committee chair of MiroMatrix, a life sciences company and since July 2022, he has served on the board of directors and as audit committee chair of Axogen, a surgical solutions company. Mr. Burke began his career as an auditor with KPMG. He received a Bachelor of Science degree in Business Administration from Bryant College.분석 기사 • Dec 24Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Recent Insider Transactions • Dec 01Insider recently bought US$117k worth of stockOn the 28th of November, Susan Schnabel bought around 25k shares on-market at roughly US$4.70 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.6m more in shares than they have sold in the last 12 months.Seeking Alpha • Oct 06ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer centerViewRay (NASDAQ:VRAY) said the SUNY Upstate Cancer Center in Syracuse, New York selected its MRIdian MRI-Guided Radiation Therapy System. The center will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to patients with pancreas, prostate, lung, liver, breast, and oligometastatic cancers, the company said in an Oct. 6 press release. ViewRay noted that to date, over 25K patients have been treated with MRIdian and currently, 54 MRIdian systems are installed at hospitals around the world.Seeking Alpha • Sep 07ViewRay's MRI-guided radiation therapy gets approval in ChinaViewRay (NASDAQ:VRAY) said its MRIdian MRI-Guided Radiation Therapy system was approved by China's National Medical Products Administration (NMPA). The approval offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART), allowing treatment which integrates diagnostic-quality MR imaging, real-time, soft tissue tracking and automated beam gating, the company said in a Sept. 7 press release. VRAY +2.15% to $3.32 premarket Sept. 7Seeking Alpha • Aug 23ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare SystemViewRay (NASDAQ:VRAY) said that the VA Houston Healthcare System has selected a MRIdian MRI-guided radiation therapy system to expand services at the Michael E. DeBakey VA Medical Center. The system will enable the VA Houston Cancer Program to offer advanced MRI-guided radiation therapy technology to veterans in the region who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers, the company said in an Aug. 23 press release. The company noted that this is the first hospital in Texas and the third VA hospital to offer MRIdian.Reported Earnings • Aug 03Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.15 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$22.1m (up 47% from 2Q 2021). Net loss: US$27.6m (loss narrowed 11% from 2Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Seeking Alpha • May 15ViewRay: Insider Buying In This $3 StockToday, we circle back on a small cap concern called ViewRay for the first time in some three years. Its core product, the MRIdian system, is gaining acceptance and order backlog and revenues continue to increase. The stock has seen some significant insider buying after its recent decline. A full investment analysis follows in the paragraphs below.Major Estimate Revision • May 13Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$94.7m to US$96.3m. EPS estimate increased from -US$0.66 per share to -US$0.59 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$7.43 unchanged from last update. Share price rose 20% to US$3.30 over the past week.Recent Insider Transactions • May 13President recently bought US$400k worth of stockOn the 11th of May, Scott Drake bought around 157k shares on-market at roughly US$2.55 per share. This was the largest purchase by an insider in the last 3 months. Scott has been a buyer over the last 12 months, purchasing a net total of US$900k worth in shares.Price Target Changed • May 09Price target decreased to US$7.43Down from US$8.38, the current price target is an average from 7 analysts. New target price is 207% above last closing price of US$2.42. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$0.57 next year compared to a net loss per share of US$0.67 last year.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.14 loss per share (up from US$0.17 loss in 1Q 2021). Revenue: US$18.9m (up 22% from 1Q 2021). Net loss: US$25.8m (loss narrowed 3.6% from 1Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 43%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.분석 기사 • Apr 22Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Recent Insider Transactions • Mar 16Insider recently bought US$96k worth of stockOn the 11th of March, Susan Schnabel bought around 25k shares on-market at roughly US$3.85 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$909k more in shares than they have sold in the last 12 months.Reported Earnings • Feb 27Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.67 loss per share (up from US$0.73 loss in FY 2020). Revenue: US$70.1m (up 23% from FY 2020). Net loss: US$110.0m (loss widened 2.0% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Nov 20Chief Financial Officer recently bought US$100k worth of stockOn the 19th of November, Zachary Stassen bought around 18k shares on-market at roughly US$5.60 per share. In the last 3 months, they made an even bigger purchase worth US$213k. Zachary has been a buyer over the last 12 months, purchasing a net total of US$313k worth in shares.Reported Earnings • Nov 07Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$19.2m (up 90% from 3Q 2020). Net loss: US$25.3m (loss narrowed 10% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Aug 26Chief Financial Officer recently bought US$213k worth of stockOn the 24th of August, Zachary Stassen bought around 40k shares on-market at roughly US$5.32 per share. This was the largest purchase by an insider in the last 3 months. This was Zachary's only on-market trade for the last 12 months.Price Target Changed • Aug 09Price target increased to US$8.03Up from US$7.41, the current price target is an average from 8 analysts. New target price is 31% above last closing price of US$6.15. Stock is up 74% over the past year.분석 기사 • Aug 09Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$15.0m (up 5.7% from 2Q 2020). Net loss: US$31.0m (loss widened 18% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Price Target Changed • May 07Price target increased to US$6.32Up from US$5.88, the current price target is an average from 8 analysts. New target price is 16% above last closing price of US$5.44. Stock is up 204% over the past year.Executive Departure • Apr 02Chief Operating Officer has left the companyOn the 31st of March, Shahriar Matin's tenure as Chief Operating Officer ended after 2.7 years in the role. As of December 2020, Shahriar personally held 434.19k shares (US$1.7m worth at the time). A total of 2 executives have left over the last 12 months.Reported Earnings • Mar 06Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$57.0m (down 35% from FY 2019). Net loss: US$107.9m (loss narrowed 10% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 26%, compared to a 21% growth forecast for the Medical Equipment industry in the US.분석 기사 • Mar 03Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) SharesWe often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...분석 기사 • Jan 27How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?The big shareholder groups in ViewRay, Inc. ( NASDAQ:VRAY ) have power over the company. Insiders often own a large...Is New 90 Day High Low • Jan 05New 90-day high: US$6.41The company is up 103% from its price of US$3.15 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.분석 기사 • Dec 22ViewRay's (NASDAQ:VRAY) Stock Price Has Reduced 56% In The Past Three YearsViewRay, Inc. ( NASDAQ:VRAY ) shareholders will doubtless be very grateful to see the share price up 30% in the last...Price Target Changed • Dec 20Price target raised to US$4.17Up from US$3.83, the current price target is an average from 8 analysts. The new target price is close to the current share price of US$4.11. As of last close, the stock is down 7.5% over the past year.Is New 90 Day High Low • Dec 09New 90-day high: US$3.97The company is up 39% from its price of US$2.85 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions • Nov 15President recently bought US$500k worth of stockOn the 10th of November, Scott Drake bought around 155k shares on-market at roughly US$3.23 per share. This was the largest purchase by an insider in the last 3 months. This was Scott's only on-market trade for the last 12 months.Is New 90 Day High Low • Nov 13New 90-day high: US$3.60The company is up 15% from its price of US$3.13 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Over the next year, revenue is forecast to grow 30%, compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.19 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$10.1m (down 52% from 3Q 2019). Net loss: US$28.1m (loss widened 35% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.매출 및 비용 세부 내역ViewRay가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VRAY.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 23106-110833331 Dec 22102-107833230 Sep 2288-107813330 Jun 2281-106773431 Mar 2273-109733331 Dec 2170-110723230 Sep 2168-109703030 Jun 2159-112722731 Mar 2158-107742531 Dec 2057-108772530 Sep 2055-117802430 Jun 2066-110882531 Mar 2082-114932531 Dec 1988-120922430 Sep 1992-102882130 Jun 1989-114812031 Mar 1975-105721831 Dec 1881-79651730 Sep 1880-87591730 Jun 1875-65491731 Mar 1859-52451631 Dec 1734-72401530 Sep 1730-59341230 Jun 1718-61321131 Mar 1718-65301131 Dec 1622-51291130 Sep 1611-54301230 Jun 1616-50281231 Mar 1616-50291231 Dec 1510-45271030 Sep 156-4126930 Jun 154-3825931 Mar 155-3420931 Dec 146-3419930 Sep 148-32161031 Dec 133-2813931 Dec 122-25108양질의 수익: VRAY.Q 은(는) 현재 수익성이 없습니다.이익 마진 증가: VRAY.Q는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VRAY.Q은 수익성이 없으며 지난 5년 동안 손실이 연평균 6.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VRAY.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VRAY.Q은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VRAY.Q는 현재 수익성이 없으므로 자본 수익률이 음수(-199.82%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/26 06:20종가2023/10/26 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ViewRay, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason BednarBairdAndrew D'SilvaB. Riley Securities, Inc.Christopher PasqualeGuggenheim Securities, LLC6명의 분석가 더 보기
Reported Earnings • May 12First quarter 2023 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.14 loss in 1Q 2022). Revenue: US$22.5m (up 19% from 1Q 2022). Net loss: US$28.9m (loss widened 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
공시 • May 10ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023ViewRay, Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023
Reported Earnings • Mar 01Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.59 loss per share (improved from US$0.67 loss in FY 2021). Revenue: US$102.2m (up 46% from FY 2021). Net loss: US$107.3m (loss narrowed 2.5% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
공시 • Feb 01ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023ViewRay, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023
Reported Earnings • Aug 03Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.15 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$22.1m (up 47% from 2Q 2021). Net loss: US$27.6m (loss narrowed 11% from 2Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.14 loss per share (up from US$0.17 loss in 1Q 2021). Revenue: US$18.9m (up 22% from 1Q 2021). Net loss: US$25.8m (loss narrowed 3.6% from 1Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 43%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Oct 27Motion For Case Conversion Approved for ViewRay, Inc.The US Bankruptcy Court gave an order granting the conversion of Chapter 11 reorganization of ViewRay, Inc. to liquidation under Chapter 7 on October 26, 2023. The debtor was facing losses in the business.
공시 • Sep 08Nasdaq To Delist the Common Stock of ViewRayNasdaq announced that it will delist the common stock of ViewRay, Inc. ViewRay, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time.
공시 • Jul 27ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite IndexViewRay, Inc. has been dropped from Nasdaq Composite Index.
공시 • Jul 24ViewRay Announces Commencement of Nasdaq Delisting ProceedingsViewRay, Inc. announced that on July 17, 2023 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’). Nasdaq has determined that due to the Company’s voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company’s ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company’s securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq’s determination. Trading of the company’s common stock will be suspended at the opening of business on July 26, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (‘SEC’), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Once the delisting from Nasdaq takes effect, the Company’s common stock is expected to begin trading on the over-the counter (‘OTC’) markets. On the OTC market, shares of the Company’s common stock, which previously traded on Nasdaq under the symbol ‘VRAY’, are expected to trade under the symbol ‘VRAYQ’. The transition to the OTC markets will not affect the Company’s intention to continue to operate in the normal course while in chapter 11. The Company will remain subject to the public reporting requirements of the SEC following the transfer.
공시 • Jul 23ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the BoardViewRay, Inc. announced that on July 19, 2023, Mr. Sai Nanduri, a Senior Investment Analyst employed by Hudson Executive Capital LP, informed the Board of Directors of the Company that Mr. Nanduri was resigning from his position as an observer to the Board, effective immediately.
공시 • Jul 17+ 1 more updateMotion for Joint Administration Filed by ViewRay, Inc.ViewRay, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on July 16, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, ViewRay Technologies, Inc., with its own case for administrative and procedural purposes. ViewRay, Inc. has been proposed as the lead debtor.
공시 • Jul 10Viewray, Inc. Announces Resignation of Susan Schnabel from Board of DirectorsOn July 1, 2023, Susan Schnabel advised the Board of Directors (the “Board”) of ViewRay, Inc. (the “Company”) of her resignation from the Board, effective immediately. Ms. Schnabel’s resignation from the Board did not result from a disagreement with the Company or any of its officers or other directors on any matters relating to the operations, policies or practices of the Company.
공시 • Jul 03ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketOn June 26, 2023, ViewRay, Inc. received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company does not currently meet the minimum closing bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Global Market at this time. The Notification Letter states that the Company has an automatic period of 180 calendar days to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the 180 calendar day period. If the Company does not achieve compliance with the minimum closing bid price requirement during the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day period if it applies to transfer the listing of the common stock to the Nasdaq Capital Market. To qualify, the Company must meet the continued listing requirement for the applicable market value of publicly held shares requirement and all other applicable initial listing standards for the Nasdaq Capital Market (except for the minimum bid price requirement) based on the Company’s most recent public filings and market information and provide written notice of its intention to cure the minimum bid price deficiency. If Nasdaq determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance with the listing requirements. The Company is committed to regaining compliance with the minimum closing bid price requirement prior to the expiration of all applicable compliance periods.
Reported Earnings • May 12First quarter 2023 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.14 loss in 1Q 2022). Revenue: US$22.5m (up 19% from 1Q 2022). Net loss: US$28.9m (loss widened 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 12Consensus revenue estimates decrease by 16%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$108.0m to US$90.8m. EPS estimate unchanged from -US$0.58 per share at last update. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$1.95 unchanged from last update. Share price fell 20% to US$0.83 over the past week.
공시 • May 10ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023ViewRay, Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023
분석 기사 • Apr 17Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% LowerThe ViewRay, Inc. ( NASDAQ:VRAY ) share price has fared very poorly over the last month, falling by a substantial 63...
Major Estimate Revision • Apr 14Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$135.8m to US$119.8m. EPS estimate increased from -US$0.602 to -US$0.585 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$7.00 to US$5.83. Share price fell 59% to US$1.30 over the past week.
Reported Earnings • Mar 01Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.59 loss per share (improved from US$0.67 loss in FY 2021). Revenue: US$102.2m (up 46% from FY 2021). Net loss: US$107.3m (loss narrowed 2.5% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
공시 • Feb 01ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023ViewRay, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023
공시 • Jan 22ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of DirectorsViewRay, Inc. announced that it has reached an agreement with Hudson Executive Capital LP to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors, effective as of January 20, 2023. The Company has also agreed that the Board will appoint Mr. Nanduri to fill any vacancy on the Board arising during the term of the agreement.
공시 • Jan 13ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage TrialViewRay, Inc. announced that findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy -- delivered with MRIdian -- to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also associated with significantly better patient- reported quality of life metrics. The MIRAGE trial was led by Amar Kishan, M.D. (first author) and Michael L. Steinberg, M.D. (senior author) at the University of California, Los Angeles (UCLA). The study was independently designed, conducted, and analyzed exclusively by UCLA. In this trial, the investigator team randomized 156 patients to receive either MRI-guided SBRT or CT-guided SBRT. Acute grade >=2 GU toxicity rates were significantly lower with MRI guidance vs. CT guidance (24.4% in the MRI group vs. 43.4% in the CT group). Acute grade >=2 GI toxicity rates were also significantly lower with MRI guidance (0.0% in the MRI group vs. 10.5% in the CT group). On multivariate analysis, which controls for differences in the use of a rectal spacer, prostate size, and baseline urinary symptoms, the MRI-guided arm was associated with a 60% reduction in odds of grade >=2 GU toxicity. More notably, there were improvements in multiple patient-reported outcomes. Significantly more patients receiving CT- guided SBRT experienced large increases in urinary symptoms, as measured by a >15 points increase in International Prostate Symptom Score (IPSS) (6.8% in the MRI group vs. 19.4% in the CT group). Similarly, a significantly greater percentage of patients experienced a clinically notable decrease in bowel-related quality of life with CT-guided, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC-26) survey (25.0% in the MRI group vs. 50.0% in the CT group). Finally, though it is too early to conclude, as more than 2/3rds of men on the trial received hormonal therapy, exploratory analysis in men who did not receive hormonal therapy showed that patient-reported sexual-function scores (by EPIC-26) decreased more in men receiving CT-guided SBRT. To date, more than 27,000 patients have been treated with MRIdian. Currently, 56 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.
공시 • Jan 10ViewRay, Inc. Announces CFO ChangesEffective January 9, 2023, William P. “Bill” Burke has been appointed as Chief Financial Officer of ViewRay, Inc. He will succeed Zach Stassen in that capacity, who has stepped down after serving the company since April 2020. Mr. Burke will become a member of the company’s executive leadership team, reporting directly to Scott Drake, President and Chief Executive Officer and will lead all aspects of the company’s finance function including business planning and analysis, accounting, SEC reporting, internal audit, tax, treasury, and investor relations. Mr. Burke, 54, is a seasoned executive, who brings over 25 years of global financial and operational experience to ViewRay. He previously served as the Chief Financial Officer at Haemonetics, a global blood management solutions company, from August 2016 to April 2022 and stayed on in an advisory capacity through June 2022. From July 2014 to July 2016, Mr. Burke served as Chief Integration Officer and Vice President, Integration for Medtronic, plc, a global healthcare products company and was a member of its Executive Committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, Mr. Burke spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Previously, he also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. Since January 2022 Mr. Burke has served on the board of directors and as audit committee chair of MiroMatrix, a life sciences company and since July 2022, he has served on the board of directors and as audit committee chair of Axogen, a surgical solutions company. Mr. Burke began his career as an auditor with KPMG. He received a Bachelor of Science degree in Business Administration from Bryant College.
분석 기사 • Dec 24Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Recent Insider Transactions • Dec 01Insider recently bought US$117k worth of stockOn the 28th of November, Susan Schnabel bought around 25k shares on-market at roughly US$4.70 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.6m more in shares than they have sold in the last 12 months.
Seeking Alpha • Oct 06ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer centerViewRay (NASDAQ:VRAY) said the SUNY Upstate Cancer Center in Syracuse, New York selected its MRIdian MRI-Guided Radiation Therapy System. The center will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to patients with pancreas, prostate, lung, liver, breast, and oligometastatic cancers, the company said in an Oct. 6 press release. ViewRay noted that to date, over 25K patients have been treated with MRIdian and currently, 54 MRIdian systems are installed at hospitals around the world.
Seeking Alpha • Sep 07ViewRay's MRI-guided radiation therapy gets approval in ChinaViewRay (NASDAQ:VRAY) said its MRIdian MRI-Guided Radiation Therapy system was approved by China's National Medical Products Administration (NMPA). The approval offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART), allowing treatment which integrates diagnostic-quality MR imaging, real-time, soft tissue tracking and automated beam gating, the company said in a Sept. 7 press release. VRAY +2.15% to $3.32 premarket Sept. 7
Seeking Alpha • Aug 23ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare SystemViewRay (NASDAQ:VRAY) said that the VA Houston Healthcare System has selected a MRIdian MRI-guided radiation therapy system to expand services at the Michael E. DeBakey VA Medical Center. The system will enable the VA Houston Cancer Program to offer advanced MRI-guided radiation therapy technology to veterans in the region who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers, the company said in an Aug. 23 press release. The company noted that this is the first hospital in Texas and the third VA hospital to offer MRIdian.
Reported Earnings • Aug 03Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.15 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$22.1m (up 47% from 2Q 2021). Net loss: US$27.6m (loss narrowed 11% from 2Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Seeking Alpha • May 15ViewRay: Insider Buying In This $3 StockToday, we circle back on a small cap concern called ViewRay for the first time in some three years. Its core product, the MRIdian system, is gaining acceptance and order backlog and revenues continue to increase. The stock has seen some significant insider buying after its recent decline. A full investment analysis follows in the paragraphs below.
Major Estimate Revision • May 13Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$94.7m to US$96.3m. EPS estimate increased from -US$0.66 per share to -US$0.59 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$7.43 unchanged from last update. Share price rose 20% to US$3.30 over the past week.
Recent Insider Transactions • May 13President recently bought US$400k worth of stockOn the 11th of May, Scott Drake bought around 157k shares on-market at roughly US$2.55 per share. This was the largest purchase by an insider in the last 3 months. Scott has been a buyer over the last 12 months, purchasing a net total of US$900k worth in shares.
Price Target Changed • May 09Price target decreased to US$7.43Down from US$8.38, the current price target is an average from 7 analysts. New target price is 207% above last closing price of US$2.42. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$0.57 next year compared to a net loss per share of US$0.67 last year.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.14 loss per share (up from US$0.17 loss in 1Q 2021). Revenue: US$18.9m (up 22% from 1Q 2021). Net loss: US$25.8m (loss narrowed 3.6% from 1Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 43%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 22Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Recent Insider Transactions • Mar 16Insider recently bought US$96k worth of stockOn the 11th of March, Susan Schnabel bought around 25k shares on-market at roughly US$3.85 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$909k more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 27Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.67 loss per share (up from US$0.73 loss in FY 2020). Revenue: US$70.1m (up 23% from FY 2020). Net loss: US$110.0m (loss widened 2.0% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Nov 20Chief Financial Officer recently bought US$100k worth of stockOn the 19th of November, Zachary Stassen bought around 18k shares on-market at roughly US$5.60 per share. In the last 3 months, they made an even bigger purchase worth US$213k. Zachary has been a buyer over the last 12 months, purchasing a net total of US$313k worth in shares.
Reported Earnings • Nov 07Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$19.2m (up 90% from 3Q 2020). Net loss: US$25.3m (loss narrowed 10% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Aug 26Chief Financial Officer recently bought US$213k worth of stockOn the 24th of August, Zachary Stassen bought around 40k shares on-market at roughly US$5.32 per share. This was the largest purchase by an insider in the last 3 months. This was Zachary's only on-market trade for the last 12 months.
Price Target Changed • Aug 09Price target increased to US$8.03Up from US$7.41, the current price target is an average from 8 analysts. New target price is 31% above last closing price of US$6.15. Stock is up 74% over the past year.
분석 기사 • Aug 09Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$15.0m (up 5.7% from 2Q 2020). Net loss: US$31.0m (loss widened 18% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Price Target Changed • May 07Price target increased to US$6.32Up from US$5.88, the current price target is an average from 8 analysts. New target price is 16% above last closing price of US$5.44. Stock is up 204% over the past year.
Executive Departure • Apr 02Chief Operating Officer has left the companyOn the 31st of March, Shahriar Matin's tenure as Chief Operating Officer ended after 2.7 years in the role. As of December 2020, Shahriar personally held 434.19k shares (US$1.7m worth at the time). A total of 2 executives have left over the last 12 months.
Reported Earnings • Mar 06Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$57.0m (down 35% from FY 2019). Net loss: US$107.9m (loss narrowed 10% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 26%, compared to a 21% growth forecast for the Medical Equipment industry in the US.
분석 기사 • Mar 03Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) SharesWe often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
분석 기사 • Jan 27How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?The big shareholder groups in ViewRay, Inc. ( NASDAQ:VRAY ) have power over the company. Insiders often own a large...
Is New 90 Day High Low • Jan 05New 90-day high: US$6.41The company is up 103% from its price of US$3.15 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
분석 기사 • Dec 22ViewRay's (NASDAQ:VRAY) Stock Price Has Reduced 56% In The Past Three YearsViewRay, Inc. ( NASDAQ:VRAY ) shareholders will doubtless be very grateful to see the share price up 30% in the last...
Price Target Changed • Dec 20Price target raised to US$4.17Up from US$3.83, the current price target is an average from 8 analysts. The new target price is close to the current share price of US$4.11. As of last close, the stock is down 7.5% over the past year.
Is New 90 Day High Low • Dec 09New 90-day high: US$3.97The company is up 39% from its price of US$2.85 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions • Nov 15President recently bought US$500k worth of stockOn the 10th of November, Scott Drake bought around 155k shares on-market at roughly US$3.23 per share. This was the largest purchase by an insider in the last 3 months. This was Scott's only on-market trade for the last 12 months.
Is New 90 Day High Low • Nov 13New 90-day high: US$3.60The company is up 15% from its price of US$3.13 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Over the next year, revenue is forecast to grow 30%, compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.19 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$10.1m (down 52% from 3Q 2019). Net loss: US$28.1m (loss widened 35% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.